Gland Pharma Q1 FY27 Earnings Review: Strategic Execution Drives 47% Profit Surge

Key Financial Highlights Profitability: Net Profit (PAT) surged by 47.1% year-over-year (YoY) to ₹317 crore, up from ₹215 crore in Q1 FY26. PAT margins expanded by approximately 330 basis points. Revenue Growth: Consolidated revenue grew 19.6% YoY to ₹1,800.2 crore. Growth was balanced, driven by equitable contributions from the CDMO (+20% YoY) and B2B (+19% YoY) segments, each comprising 50% of total revenues. Operating Performance: EBITDA witnessed a 33.1% YoY increase to ₹489.2 crore. EBITDA margins improved significantly to 27.2% (vs. 24.4% YoY), with Adjusted EBITDA margins standing at a healthy 28%. R&D Investments: R&D expenditure stood at ₹77.2 crore (₹772 million), representing 4% of consolidated revenue, strategically directed towards complex product development and regulatory filings. Operational & Strategic Milestones Pipeline & US Market Traction: The company launched four molecules in the US during the quarter and received seven new ANDA approvals, taking its cumulative approved US applications to 342. The Ready-to-Use (RTU) portfolio, addressing a $644 million US market opportunity, now includes 18 approved products out of 21 filed. Complex Injectables: Six in-house complex products have been commercialized, with three pending approval. Additionally, 15 products (seven 505(b)(2)s and eight ANDAs) are under co-development, targeting FY28 commercialization. Strategic Partnerships: Gland Pharma secured a major CDMO partnership with a global pharmaceutical firm, projecting an annualized revenue potential of $90–$100 million post-commercialization (expected CY2029). Furthermore, the company forged a strategic collaboration with Neuland Laboratories for sterile APIs and signed an in-licensing agreement for a niche liposomal product targeting US and European markets.